China National Lung Cancer Screening Guideline with Low-dose Computed
Tomography (2018 version).
10.3779/j.issn.1009-3419.2018.02.01
- Author:
Qinghua ZHOU
1
;
Yaguang FAN
2
;
Ying WANG
2
;
Youlin QIAO
3
;
Guiqi WANG
3
;
Yunchao HUANG
3
;
Xinyun WANG
2
;
Ning WU
3
;
Guozheng ZHANG
4
;
Xiangpeng ZHENG
4
;
Hong BU
5
;
Yin LI
6
;
Sen WEI
2
;
Liang'an CHEN
7
;
Chengping HU
8
;
Yuankai SHI
9
;
Yan SUN
9
Author Information
1. Lung Cancer Center/Lung Cancer Institute, West China University, Sichuan University, Chengdu 610041, China.
2. Tianjin Lung Cancer Institute, Tianjin Medical University General Hospital, Tianjin 300052, China.
3. China National Expert Group of Early Diagnosis and Treatment of Lung Cancer, Chengdu 610041, China.
4. Shanghai Huadong Hospital, Shanghai 200040, China.
5. Department of Pathology, West China Hospital, Sichuan University, Chengdu 610041, China.
6. Cancer Hospital of Henan Province, Zhengzhou 450008, China.
7. General Hospital of People's Liberation Army, Beijing 100853, China.
8. Xiangya Hospital, Central South University, Changsa 410008, China.
9. Cancer Hospital, Chinese Academy of Medical Sciences/China National Cancer Center, Beijing 100021, China.
- Publication Type:Journal Article
- Keywords:
Guideline;
High risk population;
LDCT;
Lung neoplasms;
Screening
- MeSH:
Aged;
China;
epidemiology;
Early Detection of Cancer;
Female;
Humans;
Lung Neoplasms;
diagnostic imaging;
epidemiology;
Male;
Mass Screening;
Middle Aged;
Patient Selection;
Practice Guidelines as Topic;
Radiation Dosage;
Risk;
Rural Population;
statistics & numerical data;
Tomography, Spiral Computed
- From:
Chinese Journal of Lung Cancer
2018;21(2):67-75
- CountryChina
- Language:Chinese
-
Abstract:
BACKGROUND:Lung cancer is the leading cause of cancer-related death in China. The results from a randomized controlled trial using annual low-dose computed tomography (LDCT) in specific high-risk groups demonstrated a 20% reduction in lung cancer mortality. The aim of tihs study is to establish the China National lung cancer screening guidelines for clinical practice.
METHODS:The China lung cancer early detection and treatment expert group (CLCEDTEG) established the China National Lung Cancer Screening Guideline with multidisciplinary representation including 4 thoracic surgeons, 4 thoracic radiologists, 2 medical oncologists, 2 pulmonologists, 2 pathologist, and 2 epidemiologist. Members have engaged in interdisciplinary collaborations regarding lung cancer screening and clinical care of patients with at risk for lung cancer. The expert group reviewed the literature, including screening trials in the United States and Europe and China, and discussed local best clinical practices in the China. A consensus-based guidelines, China National Lung Cancer Screening Guideline (CNLCSG), was recommended by CLCEDTEG appointed by the National Health and Family Planning Commission, based on results of the National Lung Screening Trial, systematic review of evidence related to LDCT screening, and protocol of lung cancer screening program conducted in rural China.
RESULTS:Annual lung cancer screening with LDCT is recommended for high risk individuals aged 50-74 years who have at least a 20 pack-year smoking history and who currently smoke or have quit within the past five years. Individualized decision making should be conducted before LDCT screening. LDCT screening also represents an opportunity to educate patients as to the health risks of smoking; thus, education should be integrated into the screening process in order to assist smoking cessation.
CONCLUSIONS:A lung cancer screening guideline is recommended for the high-risk population in China. Additional research , including LDCT combined with biomarkers, is needed to optimize the approach to low-dose CT screening in the future.
